ZITHROMAX (azithromycin) by Pfizer is drug. First approved in 1994.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
ZITHROMAX (azithromycin) is an oral macrolide antibiotic approved in 1994 for treating bacterial infections across respiratory, skin, and other indications. It works by inhibiting bacterial protein synthesis, making it a foundational broad-spectrum agent. The drug is formulated as an oral suspension for convenient patient dosing.
As LOE approaches, the brand team is likely consolidating and focusing on niche segments; expect smaller field teams and emphasis on managed care/payer relationships.
drug. [see Microbiology ()]
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial
Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition
Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes
Optimising Azithromycin Prevention Treatment in COPD to Reduce Exacerbations
Azithromycin Before Induction
Worked on ZITHROMAX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moZITHROMAX offers limited career growth due to mature lifecycle and approaching LOE; most opportunities involve managing generic competition, payer relations, and supply chain optimization. This is a consolidation and efficiency-focused role rather than a growth or innovation platform.